The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells (original) (raw)

References

  1. Vivier, E., Tomasello, E., Baratin, M., Walzer, T. & Ugolini, S. Functions of natural killer cells. Nat. Immunol. 9, 503–510 (2008).
    Article CAS PubMed Google Scholar
  2. Spits, H. et al. Innate lymphoid cells–a proposal for uniform nomenclature. Nat. Rev. Immunol. 13, 145–149 (2013).
    Article CAS PubMed Google Scholar
  3. Walzer, T. et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol. 8, 1337–1344 (2007).
    Article CAS PubMed Google Scholar
  4. Luci, C. et al. Influence of the transcription factor RORγt on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10, 75–82 (2009).
    Article CAS PubMed Google Scholar
  5. Sanos, S.L. et al. RORγt and commensal microflora are required for the differentiation of mucosal interleukin 22–producing NKp46+ cells. Nat. Immunol. 10, 83–91 (2009).
    Article CAS PubMed Google Scholar
  6. Satoh-Takayama, N. et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29, 958–970 (2008).
    Article CAS PubMed Google Scholar
  7. Chiossone, L. et al. Maturation of mouse NK cells is a 4-stage developmental program. Blood 113, 5488–5496 (2009).
    Article CAS PubMed Google Scholar
  8. Hayakawa, Y. & Smyth, M.J. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517–1524 (2006).
    Article CAS PubMed Google Scholar
  9. Cooper, M.A. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100, 3633–3638 (2002).
    Article CAS PubMed Google Scholar
  10. Kennedy, M.K. et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191, 771–780 (2000).
    Article CAS PubMed PubMed Central Google Scholar
  11. Lodolce, J.P. et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9, 669–676 (1998).
    Article CAS PubMed Google Scholar
  12. Vosshenrich, C.A.J. et al. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174, 1213–1221 (2005).
    Article CAS PubMed Google Scholar
  13. Mortier, E. et al. Macrophage- and dendritic-cell-derived interleukin-15 receptor α supports homeostasis of distinct CD8+ T cell subsets. Immunity 31, 811–822 (2009).
    Article CAS PubMed Google Scholar
  14. Lee, G.A. et al. Different NK cell developmental events require different levels of IL-15 trans-presentation. J. Immunol. 187, 1212–1221 (2011).
    Article CAS PubMed Google Scholar
  15. Orr, S.J., Quigley, L. & Mcvicar, D.W. In vivo expression of signaling proteins in reconstituted NK cells. J. Immunol. Meth. 340, 158–163 (2009).
    Article CAS Google Scholar
  16. Orr, S.J. et al. Implications for gene therapy-limiting expression of IL-2R c delineate differences in signaling thresholds required for lymphocyte development and maintenance. J. Immunol. 185, 1393–1403 (2010).
    Article CAS PubMed Google Scholar
  17. Eckelhart, E. et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117, 1565–1573 (2011).
    Article CAS PubMed Google Scholar
  18. Pearce, E.L. & Pearce, E.J. Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633–643 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  19. Chang, C.-H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  20. Sinclair, L.V. et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 9, 513–521 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  21. Laplante, M. & Sabatini, D.M. mTOR signaling in growth control and disease. Cell 149, 274–293 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  22. Magnuson, B., Ekim, B. & Fingar, D.C. Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks. Biochem. J. 441, 1–21 (2011).
    Article CAS Google Scholar
  23. Wang, R. & Green, D.R. Metabolic checkpoints in activated T cells. Nat. Immunol. 13, 907–915 (2012).
    Article CAS PubMed Google Scholar
  24. Baranek, T. et al. Differential responses of immune cells to type I interferon contribute to host resistance to viral infection. Cell Host Microbe 12, 571–584 (2012).
    Article CAS PubMed Google Scholar
  25. Fehniger, T.A. et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26, 798–811 (2007).
    Article CAS PubMed Google Scholar
  26. Risson, V. et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J. Cell Biol. 187, 859–874 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  27. Narni-Mancinelli, E. et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc. Natl. Acad. Sci. USA 108, 18324–18329 (2011).
    Article CAS PubMed PubMed Central Google Scholar
  28. Gordon, S.M. et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 36, 55–67 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  29. Kim, S. et al. In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3, 523–528 (2002).
    Article PubMed CAS Google Scholar
  30. Nguyen, K.B. et al. Coordinated and distinct roles for IFN-αβ, IL-12, and IL-15 regulation of NK cell responses to viral infection. J. Immunol. 169, 4279–4287 (2002).
    Article CAS PubMed Google Scholar
  31. Dokun, A.O. et al. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2, 951–956 (2001).
    Article CAS PubMed Google Scholar
  32. Sun, J.C., Ma, A. & Lanier, L.L. Cutting Edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J. Immunol. 183, 2911–2914 (2009).
    Article CAS PubMed Google Scholar
  33. Johnson, S.C., Rabinovitch, P.S. & Kaeberlein, M. mTOR is a key modulator of ageing and age-related disease. Nature 493, 338–345 (2013).
    Article CAS PubMed PubMed Central Google Scholar
  34. Feldman, M.E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
    Article PubMed CAS Google Scholar
  35. García-Martínez, J.M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
    Article PubMed CAS Google Scholar
  36. Delgoffe, G.M. et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30, 832–844 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  37. Frauwirth, K.A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769–777 (2002).
    Article CAS PubMed Google Scholar
  38. Lee, K. et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32, 743–753 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  39. Watzl, C. & Long, E.O. in Current Protocols in Immunology (ed. Coligan, J.E.) Ch. 11, Unit 11.9B (Wiley, 2010).
  40. Salmond, R.J., Emery, J., Okkenhaug, K. & Zamoyska, R. MAPK, Phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J. Immunol. 183, 7388–7397 (2009).
    Article CAS PubMed Google Scholar
  41. Frias, M.A. et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16, 1865–1870 (2006).
    Article CAS PubMed Google Scholar
  42. Finlay, D.K. et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 209, 2441–2453 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  43. Tassi, I. et al. p110gamma and p110δ phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 27, 214–227 (2007).
    Article CAS PubMed Google Scholar
  44. Guo, H., Samarakoon, A., Vanhaesebroeck, B. & Malarkannan, S. The p110 of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J. Exp. Med. 205, 2419–2435 (2008).
    Article CAS PubMed PubMed Central Google Scholar
  45. Kim, N. et al. The p110δ catalytic isoform of PI3K is a key player in NK-cell development and cytokine secretion. Blood 110, 3202–3208 (2007).
    Article CAS PubMed Google Scholar
  46. Hand, T.W. et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival. Proc. Natl. Acad. Sci. USA 107, 16601–16606 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  47. Clinthorne, J.F., Beli, E., Duriancik, D.M. & Gardner, E.M. NK cell maturation and function in C57BL/6 mice are altered by caloric restriction. J. Immunol. 190, 712–722 (2013).
    Article CAS PubMed Google Scholar
  48. Thoreen, C.C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109–113 (2012).
    Article CAS PubMed PubMed Central Google Scholar
  49. Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122–1128 (2004).
    Article CAS PubMed Google Scholar
  50. Marçais, A. et al. Regulation of mouse NK cell development and function by cytokines. Front. Immunol. 4, 450 (2013).
    Article PubMed PubMed Central CAS Google Scholar

Download references

Acknowledgements

We thank the Plateau de Biologie Expérimentale de la Souris, and the flow cytometry facility of the SFR Biosciences Gerland and of Institute for Research on Cancer and Aging, Nice (the Cytomed platform funded by the CG06, INSERM and FEDER). Supported by the FINOVI foundation (T.W. laboratory), Agence Nationale de la Recherche (for the T.W. laboratory), the European Research Council (ERC-Stg 281025 for the T.W. laboratory and a THINK Advanced Grant for the E.V. laboratory), Institut National de la Santé et de la Recherche Médicale (T.W. and E.V. laboratories), Centre National de la Recherche Scientifique (T.W. and E.V. laboratories), Université Claude Bernard Lyon1 (T.W. laboratory), Ecole Normale Superieure de Lyon (T.W. laboratory), the “Ligue contre le Cancer” (“équipe labelisée”; E.G. and E.V. laboratories) and Aix-Marseille University to Centre d'Immunologie de Marseille Luminy (E.V. laboratory).

Author information

Author notes

  1. Julien Cherfils-Vicini and Charlotte Viant: These authors contributed equally to this work.

Authors and Affiliations

  1. Centre International de Recherche en Infectiologie–International Center for Infectiology Research, Lyon, France
    Antoine Marçais, Sophie Degouve, Sébastien Viel, Jessica Rabilloud, Katia Mayol, Armelle Tavares & Thierry Walzer
  2. INSERM, U1111, Lyon, France
    Antoine Marçais, Sophie Degouve, Sébastien Viel, Jessica Rabilloud, Katia Mayol, Armelle Tavares & Thierry Walzer
  3. Ecole Normale Supérieure de Lyon, Lyon, France
    Antoine Marçais, Sophie Degouve, Sébastien Viel, Jessica Rabilloud, Katia Mayol, Armelle Tavares, Yann-Gaël Gangloff & Thierry Walzer
  4. Université Lyon 1, Lyon, France
    Antoine Marçais, Sophie Degouve, Sébastien Viel, Jessica Rabilloud, Katia Mayol, Armelle Tavares & Thierry Walzer
  5. CNRS, UMR5308, Lyon, France
    Antoine Marçais, Sophie Degouve, Sébastien Viel, Jessica Rabilloud, Katia Mayol, Armelle Tavares & Thierry Walzer
  6. Institute for Research on Cancer and Aging, Nice, Nice University, CNRS UMR7284–INSERM U1081, Faculty of Medicine, Nice, France
    Julien Cherfils-Vicini & Eric Gilson
  7. Centre d'Immunologie de Marseille-Luminy, INSERM U1104, CNRS UMR7280, Aix Marseille Université, UM2, Marseille, France
    Charlotte Viant, Aurore Fenis & Eric Vivier
  8. Laboratoire d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France
    Sébastien Viel & Jacques Bienvenu
  9. Laboratoire de Biologie Moléculaire et Cellulaire, CNRS, UMR 5239, Lyon, France
    Yann-Gaël Gangloff
  10. Department of Medical Genetics, Archet 2 Hospital, Centre Hospitalier Universitaire of Nice, Nice, France
    Eric Gilson

Authors

  1. Antoine Marçais
  2. Julien Cherfils-Vicini
  3. Charlotte Viant
  4. Sophie Degouve
  5. Sébastien Viel
  6. Aurore Fenis
  7. Jessica Rabilloud
  8. Katia Mayol
  9. Armelle Tavares
  10. Jacques Bienvenu
  11. Yann-Gaël Gangloff
  12. Eric Gilson
  13. Eric Vivier
  14. Thierry Walzer

Contributions

A.M., J.C.-V., C.V., S.D., S.V., A.F., J.R., K.M. and A.T. did experiments; T.W. designed the study with the help of A.M., J.B., Y.-G.G., E.G. and E.V.; and A.M. and T.W. wrote the manuscript.

Corresponding author

Correspondence toThierry Walzer.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Integrated supplementary information

Supplementary Figure 1 NK cell metabolism is regulated developmentally and following activation.

(a) Histograms represent FSC and SSC of BM NK (NK1.1+ CD3-CD19-) cell subsets as defined by the expression of CD27 and CD11b, one representative experiment out of 5 is shown. The bar graph shows averaged FSC and SSC MFI of BM and splenic NK cell subsets (n=5 mice in 3 independent experiments). MFI is normalized to the BM CD11blo subset. (b) Splenocytes were cultured in the presence of 100ng/ml IL-15 and analyzed after 24 to 48h. The FSC and SSC of NK cells present in the culture are shown. One representative experiment out of many is shown. (c) The FSC and SSC of NK cells from the spleen of Control or poly(I:C) injected mice are shown. One representative experiment out of many is shown. (d) The FSC and SSC of NK cells from the draining lymph nodes of Control or intranasaly Influenza infected mice at day 3 are shown. One representative experiment out of 3 is shown.

Supplementary Figure 2 mTOR activity decreases as differentiation progresses.

The bar graph shows averaged phosphoproteins MFI of BM and splenic NK cell subsets (n=4 mice in 4 independent experiments). MFI is normalized to the CD11blo subset in the BM.

Supplementary Figure 3 Gating strategies.

(a) Gating strategy employed to analyze BM, Spleen, Liver and Blood NK cells. (b) Gating strategy employed to analyze NK, ILC3 NKR+ and LTi cells in the gut.

Supplementary Figure 4 Characterization of NK-Mtor-/- mice.

(a) Representative histograms show mTOR expression in CD11blo splenic NK cells and in T cells of NK-Mtor WT/WT and NK-_Mtor_-/- mice. Staining obtained using a control isotype is shown. The bar graph shows averaged mTOR MFI among the different NK cell subsets in the BM and Spleen (n=4 mice in 3 independent experiments). Data are normalized to the CD11blo subset of the BM. Doted line represents the limit of detection. (b) The bar graph shows averaged FSC and SSC MFI of CD11blo NK cells from the BM and Spleen of NK-Mtor WT/WT and NK-_Mtor_-/- mice (n=4 mice in 3 independent experiments). (c) Histograms represent phosphorylation levels of different proteins in CD11blo NK cells from the BM of NK-Mtor WT/WT and NK-_Mtor_-/- mice. Staining obtained with an isotype control is shown. The bar graph shows the averaged MFI of different phosphoproteins as indicated (n=4 mice in 4 independent experiments). (d) Representative flow cytometric analysis showing NKp46 and RORγt expression in gut CD45+ CD19- CD3- lymphoid cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice. The bar graphs show percentages of the indicated subsets. Each point represents a single mouse (n=4 mice in 2 independent experiments).

Supplementary Figure 5 mTOR controls NK cell maturation.

(a) The bar graphs show averaged repartition of BM and Spleen NK cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice in each subset as defined by CD27 and CD11b expression (n=4 mice in 3 independent experiments. (b) Histograms show Ly49H expression level of NK cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice in each subset. The bar graphs show averaged percentage of Ly49H expressing cells among BM and Spleen NK cell of the different subsets (n=4 mice in 3 independent experiments). (c) MFI of the indicated marker was measured on CD11b- BM NK cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice. The bar graph shows the average of the ratio of MFIs NK-_Mtor_-/- over NK-Mtor WT/WT NK cells for each marker (n=3 mice in 3 independent experiments). The red line indicates a ratio of 1.

Supplementary Figure 6 mTOR is necessary for NK cell proliferation in the BM and maximal expression of IL-15R.

(a) CD45.1 Mtor WT/WT or CD45.2 Mtor lox/lox splenocytes were treated in vitro with TATCre as described in the Methods section and transferred into CD45.1/CD45.2 hosts. 3 days later, the CD45.2 Mtor lox/lox / CD45.1 Mtor WT/WT ratio in the spleen was determined. The average of 3 independent experiments is shown (n=6 mice). (b) Flow cytometric analyzes show Ki67 staining of CD11blo subset BM NK cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice. One representative experiment is shown. The bar graph shows average percentages of Ki67 positive cells (n=6 mice in 3 independent experiments). (c) The bar graph shows averaged MFI of CD122, CD132 and pSTAT5 in CD11blo BM NK cells from NK-Mtor WT/WT and NK-_Mtor_-/- mice (n=4 mice in 4 independent experiments). (d) CD122 MFI of TATCre treated NK cells of the indicated genotype was measured 3 days after transfer and is shown (n=5 mice in 3 independent experiments).

Supplementary Figure 7 Defective NK cell activation in the absence of mTOR.

(a-d) NK-Mtor WT/WT and NK-_Mtor_-/- mice were injected or not with poly(I:C) and sacrificed 18h later. Spleens were harvested and cell suspension analyzed by flow cytometry. The CD11blo NK cell subset was gated and the results are presented. (a) Histograms represent phosphorylation levels of different proteins as indicated. One representative experiment is shown (n=4). (b) Histograms represent expression of CD71, CD98 and CD69 or the level of 2-NBDG staining (n=4). The numbers indicate the geometric mean fluorescence intensity. (c) Histograms show intracellular expression of GzmB and GzmA. One representative experiment is shown (n=4). (d) Splenocytes were cultured for 1h on plates coated with the indicated antagonistic antibodies or with the indicated cytokine. Cells were subsequently stained and analyzed by flow cytometry. Flow cytometric analyzes from one representative experiment are shown for the control, NKp46 and IL-12/18 stimulation conditions. The bar graphs show the averaged percentages of CD107a and IFNγ positive cells of 3 experiments. (e) As in Fig. 6e for KLRG1 and intracellular CCL3. To assess degranulation, cells were incubated for 4h in vitro with an anti-CD107a antibody before staining. The proportion of positive NK cells for each of these markers (average +/- SD and individual mouse, statistical comparisons have been made between WT and mTOR deficient NK cells for each time point) is shown (4 independent experiments, n>6).

Supplementary Figure 8 Acute inhibition of mTOR abrogates inflammation-induced priming.

(a) Rapamycin treated or non-treated mice were injected with poly(I:C) and sacrificed 18h later. Splenocytes were analyzed by flow cytometry. The graphs show the averaged MFI for pAkt S473 in gated NK cells. Each dot represents a single mouse, bars indicate average and SD (n=9 mice in 4 independent experiments for poly(I:C) and 18 mice in 4 independent experiments for Rapa+poly(I:C)). The MFI was normalized to control non-poly(I:C) injected mice. (b) The graph shows averaged MFI of CD69 in NK cells from control or poly(I:C) injected animals, treated or not with Rapamycin (n=4 mice in 4 independent experiments). (c) Human PBMCs were cultured for 36h as indicated. Cells were then stained and analyzed by flow cytometry. The bar graphs show the averaged MFI for Perforin1 in gated NK cells (n=9 individual donors in 3 independent experiments).

Supplementary information

Rights and permissions

About this article

Cite this article

Marçais, A., Cherfils-Vicini, J., Viant, C. et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.Nat Immunol 15, 749–757 (2014). https://doi.org/10.1038/ni.2936

Download citation